Literature DB >> 621279

Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation.

K P McAdam, R J Elin, J D Sipe, S M Wolff.   

Abstract

Secondary amyloidosis is a complication of diseases characterized by recurrent acute inflammation. In this study, a standardized stimulus which induced fever and inflammation was given to six normal subjects (19-24 yr old) to follow the fluctuation in concentration of serum amyloid A (SAA), the precursor of the secondary amyloid fibril protein. After a single intramuscular injection of etiocholanolone (0.3 mg/kg), blood samples were drawn twice a day for 12 days for determination of SAA by solid phase radioimmunoassay. From a base line of <100 mug/ml, the SAA concentration began rising within 12 h to a maximum value at about 48 h of 1,350-1,800 mug/ml in three males and 380-900 mug/ml in three females and returned to base line by 4-5 days. The SAA response showed a similar time response to C-reactive protein (CRP), a well-documented acute phase protein which was assayed semiquantitatively by capillary tube precipitin reaction. CRP, but not SAA, showed a quantitative correlation with the amount of fever induced by etiocholanolone. One subject exhibited a second rise in SAA and CRP concentrations after acute over-indulgence with alcohol, suggesting that acute liver damage may have caused an acute phase reaction. Thus, a controlled episode of fever and inflammation produced a prompt and prolonged elevation of SAA and CRP concentrations. Unlike SAA, CRP has not been implicated in the pathogenesis of amyloidosis, although its relationship to the P component of amyloid has recently been established.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 621279      PMCID: PMC372549          DOI: 10.1172/JCI108949

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  COMPARISON OF HEMATOLOGIC AND FEBRILE RESPONSE TO ENDOTOXIN IN MAN.

Authors:  S M WOLFF; M RUBENSTEIN; J H MULHOLLAND; D W ALLING
Journal:  Blood       Date:  1965-08       Impact factor: 22.113

2.  Conformational flexibility of the serum amyloid precursor SAA.

Authors:  J D Sipe; K P McAdam; B F Torain; G G Glenner
Journal:  Br J Exp Pathol       Date:  1976-10

3.  Amino acid sequence similarities between amyloid P component C1t and CRP.

Authors:  Y Levo; B Frangione; E C Franklin
Journal:  Nature       Date:  1977-07-07       Impact factor: 49.962

4.  Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins).

Authors:  A P Osmand; B Friedenson; H Gewurz; R H Painter; T Hofmann; E Shelton
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

Review 5.  Amyloid, amyloidosis, and amyloidogenesis.

Authors:  G G Glenner; D L Page
Journal:  Int Rev Exp Pathol       Date:  1976

6.  Variation with age and disease of an amyloid A protein-related serum component.

Authors:  C J Rosenthal; E C Franklin
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

7.  Amyloid-related serum protein SAA from three animal species: comparison with human SAA.

Authors:  R F Anders; J B Natvig; K Sletten; G Husby; K Nordstoga
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

8.  Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation.

Authors:  M Mannik; M P Arend; A P Hall; B C Gilliland
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

9.  Some properties of antisera to serum amyloid A protein (SAA): inhibition of precipitation by complexing of SAA to albumin.

Authors:  E C Franklin
Journal:  J Exp Med       Date:  1976-12-01       Impact factor: 14.307

10.  The liver as the site of C-reactive protein formation.

Authors:  J Hurlimann; G J Thorbecke; G M Hochwald
Journal:  J Exp Med       Date:  1966-02-01       Impact factor: 14.307

View more
  34 in total

Review 1.  Anti-amyloid drugs: potential in the treatment of diseases associated with aging.

Authors:  R Kisilevsky
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

2.  A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A.

Authors:  B Kluve-Beckerman; J J Liepnieks; L Wang; M D Benson
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 3.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

4.  Monitoring the acute phase response: comparison of tumour necrosis factor (cachectin) and C-reactive protein responses in inflammatory and infectious diseases.

Authors:  C P Maury
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

5.  The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis.

Authors:  M L Baltz; D Caspi; B E Glatthaar; U Moser; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

6.  Serum amyloid A protein in acute viral infections.

Authors:  H Miwata; T Yamada; M Okada; T Kudo; H Kimura; T Morishima
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

7.  Adenoviral expression of murine serum amyloid A proteins to study amyloid fibrillogenesis.

Authors:  M S Kindy; A R King; J Yu; C Gerardot; J Whitley; F C de Beer
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

8.  Measurement of serum amyloid A protein concentrations as test of renal allograft rejection in patients with initially non-functioning grafts.

Authors:  C P Maury; A M Teppo; J Ahonen; E von Willebrand
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-04

9.  Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  C P Maury; A M Teppo; O Wegelius
Journal:  Ann Rheum Dis       Date:  1982-06       Impact factor: 19.103

10.  Monoclonal hybridoma antibodies to human amyloid related protein SAA.

Authors:  G Marhaug; G Gaudernack; B Bogen; G Husby
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.